. 2019 Apr 1;10(2):68–75. doi: 10.4103/ajm.ajm_186_19

Table 1.

Primary efficacy and safety outcomes of the AVERT trial

	Apixaban (N = 288)	Placebo (N = 275)	RR*	ARR (or RD)*	NNT*	HR (95% CI)^†	P Value^†
	n (%)	n (%)	RR*	ARR (or RD)*	NNT*	HR (95% CI)^†	P Value^†
VTE	12 (4.2)	28 (10.2)	0.41	6%	16.6	0.41 (0.26–0.65)	<0.001
Major bleeding	10 (3.5)	5 (1.8)	1.94	1.7%	58.8	2.00 (1.01–3.95)	0.046

N = total number of patients, n = number of events, RR = relative risk, ARR = absolute risk reduction, RD = risk difference, NNT = number needed to treat, HR = hazard ratio, CI = confidence interval

*Value calculated

^†Value exported from reported trial results